Everence Capital Management Inc. Purchases New Holdings in Insulet Co. (NASDAQ:PODD)

Everence Capital Management Inc. acquired a new position in shares of Insulet Co. (NASDAQ:PODD) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 1,050 shares of the medical instruments supplier’s stock, valued at approximately $274,000.

A number of other institutional investors also recently made changes to their positions in the business. GAMMA Investing LLC raised its holdings in Insulet by 44.0% in the fourth quarter. GAMMA Investing LLC now owns 2,424 shares of the medical instruments supplier’s stock valued at $633,000 after acquiring an additional 741 shares in the last quarter. Versant Capital Management Inc raised its stake in shares of Insulet by 106.1% in the 4th quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier’s stock valued at $80,000 after purchasing an additional 157 shares in the last quarter. Principal Financial Group Inc. lifted its position in shares of Insulet by 4.0% during the third quarter. Principal Financial Group Inc. now owns 86,210 shares of the medical instruments supplier’s stock worth $20,065,000 after purchasing an additional 3,355 shares during the last quarter. B. Riley Wealth Advisors Inc. acquired a new position in Insulet in the third quarter worth about $202,000. Finally, Synovus Financial Corp increased its holdings in Insulet by 36.1% in the third quarter. Synovus Financial Corp now owns 2,929 shares of the medical instruments supplier’s stock valued at $682,000 after buying an additional 777 shares during the last quarter.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Raymond James increased their target price on Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a report on Monday, October 14th. JPMorgan Chase & Co. lifted their price objective on shares of Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a report on Thursday, December 12th. Sanford C. Bernstein initiated coverage on shares of Insulet in a report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 target price on the stock. Barclays lifted their price target on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. Finally, Canaccord Genuity Group raised their target price on shares of Insulet from $269.00 to $304.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Three equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $272.81.

Insider Activity

In other news, CAO Lauren Budden sold 915 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the transaction, the chief accounting officer now owns 5,733 shares in the company, valued at approximately $1,580,129.46. This trade represents a 13.76 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 0.47% of the stock is owned by insiders.

Insulet Trading Down 1.0 %

Shares of NASDAQ:PODD opened at $265.65 on Wednesday. Insulet Co. has a twelve month low of $160.19 and a twelve month high of $279.77. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The firm has a market cap of $18.63 billion, a P/E ratio of 45.49, a P/E/G ratio of 4.12 and a beta of 1.22. The company has a 50 day moving average of $261.67 and a 200-day moving average of $229.12.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.